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Primary myelofibrosis (PMF) is a myeloproliferative neoplasm character-
ized by an excessive production of pro-inflammatory cytokines resulting in
chronic inflammation and genomic instability. Besides the driver mutations
in JAK2, MPL, and CALR genes, the deregulation of miRNA expression
may also contribute to the pathogenesis of PMF. To this end, we recently
reported the upregulation of miR-382-5p in PMF CD34+ cells. In order to
unveil the mechanistic details of the role of miR-382-5p in pathogenesis of
PMF, we performed gene expression profiling of CD34+ cells overexpress-
ing miR-382-5p. Among the downregulated genes, we identified superoxide
dismutase 2 (SOD2), which is a predicted target of miR-382-5p. Subse-
quently, we confirmed miR-382-5p/SOD2 interaction by luciferase assay
and we showed that miR-382-5p overexpression in CD34+ cells causes the
decrease in SOD2 activity leading to reactive oxygen species (ROS) accu-
mulation and oxidative DNA damage. In addition, our data indicate that
inhibition of miR-382-5p in PMF CD34+ cells restores SOD2 function,
induces ROS disposal, and reduces DNA oxidation. Since the pro-inflam-
matory cytokine transforming growth factor-b1 (TGF-b1) is a key player
in PMF pathogenesis, we further investigated the effect of TGF-b1 on
ROS and miR-382-5p levels. Our data showed that TGF-b1 treatment
enhances miR-382-5p expression and reduces SOD2 activity leading to
ROS accumulation. Finally, inhibition of TGF-b1 signaling in PMF
CD34+ cells by galunisertib significantly reduced miR-382-5p expression
and ROS accumulation and restored SOD2 activity. As a whole, this study
reports that TGF-b1/miR-382-5p/SOD2 axis deregulation in PMF cells is
linked to ROS overproduction that may contribute to enhanced oxidative
stress and inflammation. Our results suggest that galunisertib may
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represent an effective drug reducing abnormal oxidative stress induced by
TGF-b1 in PMF patients.
Database linking
GEO: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103464.
1. Introduction
Classical Philadelphia-negative chronic myeloprolifera-
tive neoplasms (MPNs) are clonal disorders of
hematopoietic stem cell that include essential thrombo-
cythemia (ET), polycythemia vera (PV), and primary
myelofibrosis (PMF; Vardiman et al., 2009) (Arber
et al., 2016). MPNs arise due to an acquired stem cell
lesion with subsequent clonal expansion leading to
proliferation and overproduction of mature myeloid
cells. PMF carries the worst prognosis among MPNs
with severe clinical hallmarks, including megakary-
ocyte and granulocyte hyperplasia, splenomegaly due
to extramedullary hematopoiesis, and bone marrow
(BM) fibrosis (Tefferi, 2005). The mutational land-
scape of MPNs has been widely studied identifying
driver mutations in JAK2, MPL, and CALR genes in
90% of PMF patients (Klampfl et al., 2013; Nangalia
et al., 2013; Pardanani et al., 2006). It is known that
the mechanism of action of these mutations results in
a constitutive activation of the JAK2/signal transducer
and activator of transcription (STAT) signaling path-
way (Araki et al., 2016; Chachoua et al., 2016; Marty
et al., 2016). The JAK/STAT signaling is a central
downstream pathway for the majority of the inflam-
matory cytokines linked to MPNs and their progres-
sion (Vainchenker and Kralovics, 2017). Indeed, PMF
patients show increased serum level of pro-inflamma-
tory cytokines (e.g., transforming growth factor-b1
(TGF-b1); interleukin (IL)-8, IL-12, IL-15), and exces-
sive production of reactive oxygen species (ROS),
which play a central role in the disease evolution
(Bjorn and Hasselbalch, 2015; Tefferi et al., 2011; Vai-
dya et al., 2012). Several findings support the patho-
genic model in which the oxidative stress contributes
to a state of chronic inflammation and genomic insta-
bility that may give rise to DNA damages promoting
disease development and progression (Yahata et al.,
2011). Moreover, the state of chronic inflammation
typical of PMF (Hasselbalch and Bjorn, 2015) is
responsible for a self-perpetuating circle in which
inflammation creates ROS that in turn create more
inflammation (Gloire et al., 2006). Marty et al.
demonstrated that the inhibition of ROS production
could prevent the development of MPNs in
JAK2V617F knock-in mouse model, giving further
evidence of the significance of oxidative stress in the
pathogenesis of these myeloid malignancies (Marty
et al., 2013).
Even though extensive studies have provided unam-
biguous proof of the role of DNA mutations in the
pathogenesis of MPNs, the genetic lesions alone do
not solely contribute to the full spectrum of the clinical
features of PMF, suggesting the existence of unknown
genetic or epigenetic cofactors (Chen et al., 2010).
In the last decade, growing evidence highlighted that
differentially expressed microRNAs (miRNAs) can
regulate fundamental processes in hematopoietic stem
and progenitor cells (HSPCs), such as proliferation,
differentiation, and malignant transformation (Bartel,
2004; Zhan et al., 2013). Of note, miRNA profile stud-
ies in MPN patients showed differentially expressed
miRNAs among different MPN subtypes (Bruchova
et al., 2007; Zini et al., 2017). Recently, our group
identified several differentially expressed genes and
miRNAs potentially involved in PMF pathogenesis
(Norfo et al., 2014). In particular, among the upregu-
lated miRNAs, we detected miR-382-5p, known to be
associated with other hematologic malignancies, such
as acute promyelocytic myeloid leukemia (AML-M3;
Jongen-Lavrencic et al., 2008); (Li et al., 2008). In our
previous work, we elucidated the role of miR-382-5p
in normal hematopoiesis and in HSPC fate demon-
strating that its enforced expression favors the granu-
locyte commitment (Zini et al., 2016).
Here we focused on the mechanistic role of miR-
382-5p in the pathogenesis of PMF, by showing its
direct involvement in ROS overproduction and oxida-
tive DNA damage induced by the inhibition of its tar-
get superoxide dismutase 2 (SOD2).
Then, as TGF-b1 has been already shown to induce
miR-382-5p expression in renal cell lines and its role in
PMF fibrosis and inflammation has been described
(Agarwal et al., 2016; Leask and Abraham, 2004), we
investigated whether TGF-b1 could take part in the
overproduction of ROS. In this study, we investigated
the link between TGF-b1 and the overproduction of
ROS. The obtained data indicate that the axis TGF-
b1/miR-382-5p/SOD2 is responsible at least in part for
the enhanced oxidative stress in normal and PMF
CD34+ cells, probably contributing to a state of
chronic inflammation, that is a typical feature of
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PMF. Finally, our study demonstrates the efficacy of
the inhibitor of TGF-beta receptor I kinase (TBRI)
galunisertib in reducing oxidative stress in PMF
CD34+ cells, unveiling a promising therapeutic appli-
cation of this drug.
2. Material and methods
2.1. Ethics statement
Human CD34+ cells were purified from umbilical cord
blood (CB) samples, collected after normal deliveries,
according to the institutional guidelines for discarded
material (Clearance of Ethical Committee for Human
experimentation of Modena: Secretary office Saverio
Santachiara, approval date: 18.01.2005; approval file
number # 793/CE).
Primary myelofibrosis CD34+ cells were isolated
from the peripheral blood (PB) of three patients in a
typical fibrotic phase of the disease according to
World Health Organization (WHO) criteria updated in
2016 (Arber et al., 2016). The study was performed
under the local institutional review board’s approved
protocol (Florence: approval date: April 22, 2011,
approval file number # 2011/0014777; Pavia: approval
date: February 24, 2011, file number #174). All sub-
jects provided informed written consent, and the study
was carried out in accordance with the Declaration of
Helsinki.
2.2. CD34+ cell purification and culture
Human CD34+ cells were purified from CB or PB
samples as previously described (Bianchi et al., 2010;
Norfo et al., 2014). After immunomagnetic separation,
CD34+ cells were seeded into 24-well plates at 5 9 105
per mL in SYN-H synthetic serum-free medium
(ABCell-Bio, Paris, France) supplemented with stem
cell factor (SCF; 50 ngmL1), FLT3-ligand (FLT3L;
50 ngmL1), thrombopoietin (TPO; 20 ngmL1), IL-6
(10 ngmL1) and IL-3 (10 ngmL1; all from Miltenyi
Biotec, Auburn, CA, USA) and electroporated 24 h
later.
2.3. TGF-b1 and galunisertib treatment
Purified CB CD34+ cells were seeded into 24-well
plates at 5 9 105 per mL in SYN-H medium (ABCell-
Bio) without any other supplements and treated with
TGF-b1 (5 ngmL1; Miltenyi Biotec) for 24 and 48 h.
The TGF-b receptor I kinase (ALK5) inhibitor, galu-
nisertib (LY-2157299, Catalog #S2230, Aurogene,
Rome, Italy), was prepared at 10 mM in dimethyl
sulfoxide (DMSO) and stored in aliquots at 20 °C.
PMF CD34+ cells were incubated for 24 h with
500 nM galunisertib (Zhou et al., 2011).
2.4. Electroporation of CD34+ cells
In order to achieve the overexpression of miR-382-5p
in HSPCs, CB CD34+ cells were electroporated using
4D-Nucleofector System (Lonza Group Ltd, Basel,
Switzerland) as described (Norfo et al., 2014). Briefly,
24 h after immunomagnetic separation, CD34+ cells
were electroporated twice, once every 24 h, with 3 lg
(0.214 nM) of mirVana miR-382-5p mimic or mirVana
miRNA mimic Negative Control (mimic-Neg; Life
Technologies, Carlsbad, CA, USA). Preliminary exper-
iments were carried out using untransfected and
MOCK-transfected samples as additional controls. For
each electroporation, 4 9 105 CD34+ cells were resus-
pended in 100 lL of P3 Primary Cell Solution (Lonza)
containing mimic miRNA, and pulsed with the pro-
gram DS112. After each transfection, CD34+ cells
were transferred into prewarmed fresh SYN-H med-
ium (ABCell-Bio) supplemented with SCF
(50 ngmL1), FLT3L (50 ngmL1), TPO (20
ngmL1), IL-6 (10 ngmL1), and IL-3 (10 ngmL1)
and maintained in the same culture conditions as
described above. In order to estimate the transfection
efficiency, we used BLOCK-IT fluorescent oligo (cata-
log #13750062, ThermoFisher Inc., Waltham, MA,
USA). Briefly, CD34+ cells were nucleofected twice,
once every 24 h, with 0.214 nM of BLOCK-IT fluores-
cent oligo and FITC fluorescence was detected by flow
cytometry at 24 and 48 h after the last nucleofection.
Primary myelofibrosis CD34+ cells underwent the
same electroporation protocol DS112 and were nucleo-
fected 3 times, once every 24 h, with 3 lg of mirVana
miR-382-5p inhibitor or mirVana miRNA Inhibitor
Negative Control (anti-miR-Neg).
Cells were analyzed 24 and 48 h after the last nucle-
ofection for both cell viability and miR-382-5p and
SOD2 expression.
2.5. RNA extraction and gene expression profile
miRNeasy micro RNA isolation kit (Qiagen, Hilden,
Germany) was used to isolate and purify total RNA
containing small RNAs from CD34+ cells, following
the manufacturer’s instructions. The purity and integ-
rity of RNA samples were determined by using
disposable RNA chips (Agilent RNA 6000 Nano Lab-
Chip kit) and the Agilent 2100 Bioanalyzer (Agilent
Technologies, Waldbrunn, Germany). NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies,
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Wilmington, DE, USA) was used to evaluate the RNA
sample concentration, while 260/280 and 260/230 nm
ratios were used to assess the RNA purity.
Gene expression profiling was performed in tripli-
cate starting from 100 ng of total RNA obtained from
three independent experiments. For microarray analy-
sis, cDNA synthesis and biotin-labeled target synthesis
were performed using the GeneAtlas 30 IVT Plus
Reagent Kit according to the standard protocol sup-
plied by Affymetrix (Santa Clara, CA, USA). The
HG-U219 Array Strip (Affymetrix) hybridization,
staining, and scanning were performed by using the
GeneAtlas Platform.
Gene expression profile (GEP) data were analyzed
by PARTEK GS 6.6 Software Package and normalized
using the robust multi-array average (RMA) procedure
(Irizarry et al., 2003). Differentially expressed genes
were selected as the sequences showing a signal-log
ratio average > 0.4 or < 0.4 in the pairwise compar-
isons between miR-382-5p mimic and negative control
samples (mimic-Neg). Microarray data were analyzed
with the two-tailed Student’s t-test for comparison of
signal averages in paired samples; P < 0.05 was con-
sidered significant. Analysis of variance (ANOVA) mod-
ule included in PARTEK GS 6.6 Software Package was
used for selection of differentially expressed genes
shown in the heatmap. Ingenuity pathways analysis
(IPA; www.ingenuity.com) was used to find the puta-
tive miRNA-mRNA interactions through IPA’s
MicroRNA Target Filter.
2.6. Quantitative RT-PCR (qRT-PCR)
Total RNA (50 ng per sample) was reverse-transcribed
to cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Life Technologies), and real-time
PCR was achieved in triplicate with TaqMan gene
expression assays and Fast advanced master mix (all
reagents from Life Technologies) by using the AB
7900HT Fast Real-Time PCR System (Applied Biosys-
tems; Guglielmelli et al., 2007a,b). Relative quantity
(RQ) was carried out using the comparative cycle
threshold (CT) method using glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) as the housekeeping
gene. To normalize the data, DDCT was calculated for
each sample using the mean of its DCT values sub-
tracted from the mean DCT value measured in the
entire population of healthy subjects, considered as a
calibrator; the RQ value was expressed as 2DDCT.
Individual miRNA detection was performed in trip-
licate using the TaqMan MicroRNA assays (Life tech-
nologies) by means of qRT-PCR. Briefly, 5 ng of total
RNA was reverse-transcribed using the TaqMan
MicroRNA Reverse Transcription Kit and miRNA-
specific looped primers. miRNA expression RQ data
were calculated as reported above, by using U6
snRNA as the housekeeping control (Norfo et al.,
2014).
2.7. Western blotting
Briefly, CB or PMF CD34+ was lysed in 50 mM Tris
pH 7.4, 150 mM NaCl, 10 mM KCl, 1 mM EDTA,
20 mM NaF, 5 mM DTT, 0,25% Na deoxycholate,
0,1% Nonidet P-40 and protease inhibitor (Complete,
catalog #1697468, Roche, Milano, Italy). Total cell
lysates (30 mgmL1 for each sample) were resolved
by electrophoresis on a 10% SDS/polyacrylamide gel
and transferred to nitrocellulose membrane (GE
Healthcare, Little Chalfont, UK). The membranes
were checked for loading and transfer efficiency by
staining with Red Ponceau. Membranes were blocked
with 5% BSA in 0,1% Tween-20 for 1 h at room
temperature (RT), washed, and incubated with pri-
mary antibodies: (a) mouse monoclonal anti-SOD2
antibody (1 : 20 000 dilution, SOD-2 (A-2) catalog
#sc-133134, Santa Cruz Biotechnology, Inc., Heidel-
berg, Germany) overnight at 4 °C; (b) rabbit poly-
clonal anti-actin antibody (1 : 2000 dilution, Thermo
Fisher Scientific, Inc., Waltham, MA, USA, catalog
#PA1-16889) for 1 h at RT. Horseradish peroxidase-
conjugated goat anti-mouse and anti-rabbit antibodies
(catalog #sc2005, #sc2004 Santa Cruz Biotechnology
Inc) were added at 1 : 5000 and 1 : 10 000, respec-
tively, for 1 h at RT. BM Chemiluminescence Blot-
ting Substrate (POD; Roche) visualized proteins.
IMAGEJ software was used to quantify the protein
level.
2.8. Luciferase reporter analysis
The 30-UTR reporter analysis was performed to verify
the real interaction between miR-382-5p and its target
sequence on SOD2 30UTR. Briefly, predicted target
site of miR-382-5p was cloned into the Pme1 and Xbal
sites of pmirGLO Dual-Luciferase miRNA Target
Expression Vector (Promega Italia, Milano, Italy).
Synthetic oligonucleotides (wild-type (WT) miRNA-
binding site: 50AAACTAGCGGCCGCTAGTTCAC
TTATTTCATAAACAACTTAT30, 30TTTGATCGC
CGGCGATCAAGTGAATAAAGTATTTGTTGAAT
AGATC50) were designed based on TargetScanHuman
Database 7.0 sequences and correspond to 16 nucleo-
tides surrounding the miRNA-binding sites (seed
region) sequence that were annealed before ligation
into the pmirGlo plasmid. Mutations in the seed
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region and luciferase reporter assay in K562 cell line
have been performed as previously described (Zini
et al., 2016). Briefly, K562 cells were cotransfected by
means of the Amaxa 4D-NucleofectorTM System with
either a miR-382-5p or mimic-Neg at a concentration
of 3.6 lM and with either empty vector or miRNA-
binding site-containing construct (200 ngsample1).
Firefly and Renilla luciferase activities were measured
at 36 and 48 h after electroporation using the Dual-
Luciferase Reporter Assay System (Promega), and
luminescence was recorded on a GloMax-Multi+
Detection System with Instinct Software (Promega),
according to the manufacturer’s protocol. Data nor-
malization was performed as previously described (Zini
et al., 2016).
2.9. Detection of ROS using CM-H2DCFDA
The redox-sensitive fluorochrome 5-(and 6)-chloro-
methyl-20, 70-dichlorodihydrofluorescein diacetate dye
(CM-H2DCFDA, Invitrogen, Carlsbad, CA, USA)
was used to measure the intracellular ROS. In order to
perform dichlorofluorescein (DCF) staining, 24 h after
the last nucleofection, CB or PMF CD34+ cells were
loaded with 2 lM CM-H2DCFDA for 20 min at
37 °C.
Before flow cytometric analysis, the cells were
removed from loading buffer and incubated in growth
medium for 20 min at 37 °C (Marty et al., 2013). Data
acquisition and analysis were conducted using a BD
FACSCanto II (BD Biosciences, San Jose, CA USA).
At least 10 000 events were detected for each sample
to guarantee a statistical relevance.
2.10. Determination of superoxide dismutase
activity in CB and PMF CD34+ cells
Superoxide dismutase (SOD) activity was measured
24 h after the last nucleofection using Trevigen’s
Superoxide Dismutase Assay Kit according to the
manufacturer’s instructions (Trevigen, Gaithersburg,
MD, USA). SOD activity was assayed on 20 lg of
total cellular lysate, based on the reduction in nitrob-
lue tetrazolium (NBT) to nitroblue tetrazolium-difor-
mazan. Since SODs reduce superoxide ion
concentration, the reduction in the nitroblue tetra-
zolium-diformazan production is a measure of total
SOD activity (UmL1), defined as the amount of
enzyme needed to display 50% dismutation of the
superoxide radicals. The reduction in nitroblue tetra-
zolium to nitroblue tetrazolium-diformazan induced
by the superoxide radical (O2 ) was monitored with
Beckman Coulter DU730 Life Science UV/VIS
spectrophotometer by reading the absorbance at
550 nm.
2.11. Measurement of 8-OH-dG level
Oxidative DNA damage was detected in CB and PMF
CD34+ cells 24 h after the last nucleofection by mea-
suring the formation of 80hydroxy-20deoxyguanosine
(8-OH-dG), a ubiquitous marker of oxidative stress.
Firstly, DNA was isolated using DNeasy Blood and
Tissue Kit (Qiagen, Valencia, CA, USA) and the
obtained RNA-free DNA was used to estimate 8-OH-
dG levels using a competitive enzyme immunoassay
according to the manufacturer’s protocol (The OxiS-
electTM Oxidative DNA Damage ELISA Kit, Cell Bio-
labs, San Diego, CA, USA). 8-OH-dG concentration
was determined by measuring the absorbance at
450 nm with the Glomax Multi Detection System
(Promega, Madison, WI, USA).
2.12. Measurement of CB and PMF CD34+ cell
viability
Viability measurement was assessed by trypan blue
exclusion assay 24 h after the last nucleofection
(Humpe et al., 2005). In a Neubauer chamber, at least
100 cells were microscopically analyzed in triplicate for
cell viability. The mean percentage of living cells of
the three analyses was calculated. Furthermore, cell
viability was evaluated using XTT Cell Proliferation
Assay Kit (Trevigen) in accordance with the manufac-
turer’s instruction. After 24 h from the last nucleofec-
tion, CD34+ cells were plated at a density of
50 000 cells/well in 96-well plates. The optical density
at 450 nm was measured at 2, 4, 6, 8, and 24 h by
Glomax Multi Detection System (Promega).
2.13. SOD2 and Ki-67 immunofluorescent
staining
After 24 h from the last nucleofection, 1 9 104 CB or
PMF CD34+ cells were cytocentrifuged, fixed with 4%
paraformaldehyde, and permeabilized using 0,2% Tri-
ton X-100 in PBS for 20 min. After blocking with 2%
BSA, 0,1% Triton in PBS, slides were incubated with
rabbit polyclonal anti-human Ki-67 (catalog
#ab15580, Abcam, Cambridge, UK) at 1 : 100 dilution
in the blocking buffer for 30 min at 37 °C or with
mouse monoclonal anti-SOD2 antibody (catalog #sc-
133134, Santa Cruz Biotechnology Inc.) at 1 : 100
dilution in the blocking buffer overnight at 4 °C. After
three washes in PBS, slides were incubated for 30 min
at 37 °C with goat anti-rabbit Alexa Fluor 568-
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conjugated secondary antibody at 1 : 2000 dilution
(catalog #A-11011 Invitrogen) or goat anti-mouse
Alexa Fluor 488-conjugated secondary antibody at
1 : 1000 dilution (catalog # A-11004 Invitrogen). The
slides were rinsed again, and 40,6-diamidino-2-pheny-
lindole (DAPI) solution was applied for 3 min for
nuclear counterstaining. Fluorescent imaging was per-
formed using a high-resolution Zeiss LSM 510 Meta
Confocal fluorescence microscope (Zeiss, Germany)
equipped with AXIOVISION software for image analysis.
To ensure random sampling, 20 images/slide were
taken and cells positive for Ki-67 or SOD2 were
scored.
2.14. Ki-67 Flow cytometry analysis
Ki-67 expression was analyzed by flow cytometry. Ki-
67 intracellular staining was performed using FIX &
Fig. 1. miR-382-5p overexpression in CB
CD34+ cells. (A) Expression of miR-382-5p
in CB CD34+ cells was assessed by
means of qRT-PCR at 24 and 48 h after
the last nucleofection and data are
reported as RQ. U6 snRNA was used as
internal controls, and mimic-Neg was
used as reference sample. The results are
representative of six independent
experiments and are expressed as the
mean  SEM. Two-tailed Student’s t-test:
**P < .01 versus mimic-Neg. (B) GEP of
biological triplicates of miR-382-5p-
overexpressing cells and mimic-Neg
control samples. The heatmap was
computed on a gene list selected by
ANOVA using the clustering algorithm
included in the Partek GS package (Partek
Incorporated, St Louis, MO, USA) by
means of Euclidean distance and average
linkage. Gene coloring is based on
normalized signals, as shown at the
bottom of the figure; green indicates
reduced expression; red increased
expression. Gene symbol is indicated on
the right. Mir-382 and mimic-Neg groups
clustered separately in the dendrogram
shown at the top of the heat map.
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PERM Cell Fixation & Cell Permeabilization Kit
(ThermoFisher Scientific Inc., Waltham, MA, USA).
Briefly, 24 h after the last nucleofection, 1 9 105 cells
were fixed for 15 min at RT in reagent A and subse-
quently fixed in 100% methanol for 10 min at 4 °C.
Then, fixed cells were washed with PBS and permeabi-
lized with reagent B for 30 min at RT with rabbit
polyclonal anti-human Ki-67 (#ab15580, Abcam) at
1 : 250 dilution. Finally, cells were washed with PBS
and incubated with fluorescein isothiocyanate goat
anti-rabbit IgG F(ab0)2 fragment (#F0382, Sigma-
Aldrich, St. Louis, MO, USA) for 30 min at RT. Data
acquisition and analysis were performed using a BD
FACSCanto II (BD Biosciences). At least 10 000
events were detected for each sample to guarantee a
statistical relevance.
2.15. Statistical analysis
The statistics used for data analysis were based on
two-tailed Student’s t-tests for averages comparison in
paired samples. Data were analyzed by using Micro-
soft Excel (Microsoft Office, 2008 release) and are
reported as mean  standard error of the mean
(SEM). P < 0.05 was considered significant.
2.16. Data accessibility
All microarray data were submitted to the Gene
Expression Omnibus repository (http://www.ncbi.nlm.
nih.gov/geo). GEP data referring to miR-382-5p-over-
expressing CD34+ cells can be downloaded at the link
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE103464). GEP data related to PMF CD34+ cells
are available as series in the Gene Expression Omnibus
repository (GSE41812 and GSE53482).
3. Results
3.1. Gene expression profile (GEP) of miR-382-5p-
overexpressing cells
In order to investigate the possible role of miR-382-5p
in the pathogenesis of PMF, we performed a GEP in
CD34+ cells overexpressing miR-382-5p.
miRNA overexpression was achieved by nucleofec-
tion of miR-382-5p mimic. First, we assessed the
transfection efficiency using BLOCK-IT fluorescent
oligo and we showed that the proportion of trans-
fected cells is more than 90% (Fig. S1). As shown in
Fig. 1A, we obtained a significant overexpression of
miR-382-5p upon miRNA mimic transfection at 24
and 48 h after the last nucleofection, which was
maintained at least until 96 h (data not shown). The
expression level of miR-382-5p in the three different
control samples (i.e., untransfected cells, MOCK-
transfected cells, and cells transfected with miRNA
mimic negative control or mimic-Neg) was not chan-
ged (Fig. 1A). Based on these data, we selected the
mimic-Neg sample as negative control and we
included it in each experiment.
Microarray analysis was performed 24 h after the
last nucleofection, the time point in which miR-382-5p
expression level achieves the best upregulation in
CD34+ cells, as depicted in Fig. 1A. Using the filtering
procedure described in Methods, we generated a list of
97 genes significantly modulated in miR-382-5p-over-
expressing cells (miR-382-5p) compared to mimic-Neg
sample (Table S1). Fig. 1B shows the heatmap of dif-
ferentially expressed genes further selected by ANOVA
(P value < 0.05). Among the 75 downregulated genes,
we identified SOD2, which is one of the most
Fig. 2. SOD2 is a target of miR-382-5p. (A) Expression of SOD2 mRNA in CB CD34+ cells overexpressing miR-382-5p. The SOD2 level was
assessed by qRT-PCR 24 and 48 h after the last nucleofection. GAPDH was used as housekeeping gene, and mimic-Neg was used as
reference sample. Data are reported as RQ. The results come from six independent experiments. (B) Sequence of oligonucleotides
containing the WT miRNA-binding site in 30-UTR of SOD2 mRNA as predicted by TargetScanHuman Database (Release 7.0) and the
mismatched (mutated) version of this target site. miR-382-5p seed region is shown in red. Mutated nucleotides are in lowercase.
(C) Validation of SOD2 as miR-382-5p target by dual-luciferase reporter assay. K562 cells were cotransfected with the construct containing
the putative WT or mutated miR-382-5p binding site. Firefly luciferase activity was measured at 36 and 48 h in K562-transfected cells, and
data were normalized to Renilla luciferase activity. Each bar represents the luciferase activity upon miRNA overexpression normalized on the
value of the same 30-UTR luciferase vector upon mimic-Neg transfection. The results come from three independent experiments.
(D) Western blot analysis of SOD2 protein level in whole-cell lysate from CB CD34+ cells transduced with miR-382-5p or mimic-Neg at 24
and 48 h after the last nucleofection. b-Actin was used as loading control. (E) Representative image of SOD2 immunofluorescence analysis
in CB CD34+ cells overexpressing miR-382-5p or transfected with mimic-Neg at 24 h after the last nucleofection. Cells were labeled with
anti-SOD2 antibody (green fluorescence), and nuclear counterstaining was performed with DAPI (blue fluorescence). Scale bar: 20 lm.
Original magnification = 40X. To ensure random sampling, 20 images/slide were captured and cells positive for SOD2 were scored.
Fluorescence imaging was performed using the Zeiss LSM 510 Meta Confocal Microscope. (F) Quantification of SOD2 positivity in CB
CD34+ cells overexpressing miR-382-5p compared to negative control. At least 200 cells for each experiment were scored. The results
come from six independent experiments. Values are reported as mean  standard error of the mean (SEM). Two-tailed Student’s t-test:
**P < .01 versus mimic-Neg; *P < .05 versus mimic-Neg.
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Fig. 3. mir-382-5p overexpression in CB
CD34+ cells reduces SOD activity, and
increases ROS production and oxidative
DNA damage. (A) Effect of miR-382-5p
overexpression on SOD activity (UmL1)
determined 24 h after the last
nucleofection. (B) The intracellular level of
ROS in miR-382-5p and mimic-Neg was
measured using DCF staining by flow
cytometric analysis 24 h after the last
nucleofection. (C) Representative flow
cytometry dot plots showing the side
scatter (SSC) versus DCF fluorescence
distribution in miR-382-5p-overexpressing
cells and mimic-Neg sample at 24 h after
the last nucleofection. (D) The level of 8-
OH-dG in miR-382-5p and mimic-Neg was
measured at 24 h after the last
nucleofection. The results are
representative of six independent
experiments and are expressed as the
mean  SEM. Two-tailed Student’s t-test:
**P < .01 versus mimic-Neg; *P < .05
versus mimic-Neg.
Fig. 4. miR-382-5p overexpression increases proliferation of CB CD34+ cells. (A) Viability measurement was assessed by cell count
(cellsmL1) 24 h after the last nucleofection by trypan blue exclusion assay. (B) The proliferation rate was evaluated at 24 h after the last
nucleofection using XTT Cell Proliferation Assay (Trevigen). CD34+ cells were plated at a density of 50 000 cells/well in a 96-well plate. The
absorbance at 450 nm was monitored at different time points. (C) Flow cytometric analysis to estimate the number of proliferating cells
using Ki-67-antibody. The histogram shows the percentage of Ki-67-positive cells in miR-382-5p sample compared to negative control at
24 h after the last nucleofection. (D) Representative image of Ki-67 immunofluorescence analysis in miR-382-5p and mimic-Neg transfected
CD34+ cells at 24 h after the last nucleofection. Cells were labeled with anti-Ki-67 antibody (red fluorescence), and nuclear counterstaining
was performed with DAPI (blue fluorescence). Scale bar, 20 lm. Original magnification = 40X. To ensure random sampling, 20 images/slide
were captured and cells positive for Ki-67 were scored. Fluorescence imaging was performed using the Zeiss LSM 510 Meta Confocal
Microscope. (E) Quantification of Ki-67 positivity in CD34+-overexpressing cells compared to negative control. At least 200 cells for each
experiment were scored. The results are representative of three independent experiments and are expressed as the mean  SEM. Two-
tailed Student’s t-test: **P < .01 versus mimic-Neg; *P < .05 versus mimic-Neg.
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favorable predicted targets of miR-382-5p (context
score 0.59) according to TargetScanHuman Database
(Table S2). Interestingly, GEP analysis of PMF
CD34+ cells showed that SOD2 mRNA is significantly
decreased in PMF patients compared to healthy
donors (Fig. S2; Norfo et al., 2014).
The SODs are a family of antioxidant enzymes that
catalyze the dismutation of superoxide radical anions
into hydrogen peroxide. In particular, manganese
superoxide dismutase (MnSOD-SOD2) has emerged
as a crucial tumor suppressor gene and a key media-
tor in the mitochondrial clearance of detrimental
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ROS (Van Remmen et al., 2003). Since ROS play a
crucial role in disease progression of MPNs (Bjorn
and Hasselbalch, 2015), we decided to investigate the
possible involvement of the miR-382-5p/SOD2 axis in
the induction of oxidative stress in normal and PMF
CD34+ cells.
3.2. SOD2 is a target of miR-382-5p
In order to validate the negative correlation between
miR-382-5p and SOD2 expression in CD34+ cells, we
measured the level of SOD2 in miR-382-5p-overexpres-
sing cells. As shown in Fig. 2A, SOD2 mRNA is signifi-
cantly downregulated upon miR-382-5p overexpression
at 24 and 48 h after the last nucleofection. Then, to con-
firm that SOD2 is a real target of miR-382-5p, we per-
formed a luciferase reporter assay, by cloning the
predicted miRNA-binding site of SOD2 downstream of
firefly luciferase gene in Dual Luciferase pmirGLO vec-
tor (Fig. 2B). Transient cotransfection of either miR-
382-5p or mimic-Neg with WT or mutated miRNA-
binding site was performed in K562 cells. As shown in
Fig. 2C, luciferase activity is significantly decreased by
miR-382-5p overexpression when K562 cells were trans-
fected with the construct containing the WT miRNA-
binding site of SOD2. Mutations in the seed region-
binding side abrogate the effect of miR-382-5p overex-
pression. Furthermore, we confirmed that miR-382-5p
overexpression induces a reduction in SOD2 protein
level at 24 and 48 h after the last nucleofection
(Fig. 2D). Immunofluorescence for SOD2 showed a sig-
nificant reduction in SOD2 in miR-382-5p-overexpres-
sing cells compared to mimic-Neg (Fig. 2E,F).
3.3. miR-382-5p overexpression reduces SOD2
activity, and increases ROS production and
oxidative DNA damage
Superoxide dismutase 2 is the major mitochondrial
enzyme responsible for superoxide dismutation,
preventing the production and accumulation of
potentially damaging ROS. For this reason, we won-
dered whether miR-382-5p overexpression could
affect SOD2 activity by assaying for superoxide dis-
mutase reaction using Trevigen’s Superoxide Dismu-
tase Assay Kit. Fig. 3A shows that the SOD activity
is significantly decreased in miR-382-5p-overexpres-
sing cells compared to negative control. Then, by
using CM-H2DCFDA staining, we detected an accu-
mulation of ROS in miR-382-5p-overexpressing
CD34+ cells (Fig. 3B,C). Since the enhanced produc-
tion of ROS can lead to DNA damage in
hematopoietic stem cells (Yahata et al., 2011), we
measured DNA 8-OH-dG level, a known marker of
oxidative stress-mediated DNA damage. As shown in
Fig. 3D, we demonstrated a significant increase in 8-
OH-dG level in cells overexpressing miR-382-5p
compared to negative control.
These results suggest that miR-382-5p, through the
inhibition of its target SOD2, causes an increase in
intracellular ROS level, which in turn leads to the
DNA damage.
3.4. miR-382-5p overexpression increases
proliferation of CD34+ cells
Since SOD2 has been already described as a tumor
suppressor gene and an inverse correlation between
its expression level and proliferation rate has been
already reported in HSPCs (Hurt et al., 2007), we
investigated the role of miR-382-5p in CD34+ cell
proliferation.
First of all, trypan blue exclusion assay highlighted
a significant increase in cell count in miR-382-5p com-
pared to mimic-Neg sample (Fig. 4A). Moreover, as
shown in Fig. 4B, the effect of miR-382-5p on cell via-
bility was further confirmed by XTT assay. Accord-
ingly, flow cytometry analysis showed that cells
overexpressing miR-382-5p display a high positivity
for Ki-67 antigen, expressed in all proliferating cells
Fig. 5. Inhibition of miR-382-5p reduces oxidative stress in PMF CD34+ cells. (A,B) Expression level of miR-382-5p and SOD2 in PMF
CD34+ cells 24 and 48 h after the last nucleofection by means of qRT-PCR. Data are reported as RQ. U6 snRNA and GAPDH were used as
internal controls, and anti-miR-Neg was used as calibrator sample. (C) Immunoblotting of SOD2 protein level in lysates from anti-miR-Neg
and anti-miR-382-5p transfected PMF CD34+ cells at 48 h after the last nucleofection. b-actin protein level is reported as loading control. (D)
Representative image of immunofluorescence analysis using SOD2-antibody (green fluorescence) in PMF CD34+ cells transfected with miR-
382-5p inhibitor or anti-miR-Neg at 48 h after the last nucleofection. Nuclear counterstaining was performed with DAPI (blue fluorescence).
Scale bar, 20 lm. Original magnification = 40X. To ensure random sampling, 20 images/slide were captured and cells positive for SOD2
were scored. Fluorescence imaging was performed using the Zeiss LSM 510 Meta Confocal Microscope. (E) Quantification of SOD2
positivity in PMF CD34+ cells after miRNA inhibition. At least 200 cells for each experiment were scored. (F) Effect of miR-382-5p inhibition
on SOD activity (UmL1) determined 48 h after the last nucleofection. (G) Quantification of intracellular ROS level measured by DCF
staining 48 h after the last nucleofection. (H) ROS-induced DNA damage was measured through the level of 8-OH-dG at 48 h after the last
nucleofection. Values are reported as mean  standard error of the mean (SEM). Two-tailed Student’s t-test: ***P < .001 versus anti-miR-
Neg **P < .01 versus anti-miR-Neg; *P < .05 versus anti-miR-Neg.
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(Fig. 4C; Whitfield et al., 2006); (Sobecki et al., 2016).
Finally, the immunofluorescence staining using an
anti-Ki-67 antibody demonstrated that miR-382-5p
overexpression leads to an increased percentage of Ki-
67-positive cells (Fig. 4D–E).
Altogether, these results suggest a positive effect of
miR-382-5p on CD34+ cell proliferation.
3.5. Inhibition of miR-382-5p reduces oxidative
stress and decreases cell proliferation of PMF
CD34+ cells
In order to clarify whether miR-382-5p could be a key
player in PMF pathogenesis by promoting ROS over-
production in hematopoietic progenitors, we inhibited
miR-382-5p in PMF CD34+ cells by transient transfec-
tion of mirVana miRNA inhibitor. As shown in
Fig. 5A, we obtained a significant reduction in miR-
382-5p expression level at 24 and 48 h after the last
nucleofection. At the same time points, we evaluated
SOD2 expression, demonstrating a relevant increase in
SOD2 at both mRNA and protein level at 48 h after
last nucleofection (Fig. 5B,C). These results were con-
firmed by SOD2 immunofluorescence analysis that
shows a strong increase in protein expression in PMF
CD34+ cells upon miR-382-5p downregulation
(Fig. 5D–E). Moreover, miR-382-5p inhibition restores
SOD activity (Fig. 5F), causes a decrease in ROS
accumulation (Fig. 5G), and leads to a significant
reduction in oxidative stress-mediated DNA damage
(Fig. 5H).
Interestingly, trypan blue exclusion assay highlighted
a significant decrease in cell count upon miR-382-5p
inhibition (Fig. 6A). Furthermore, flow cytometry
analysis for Ki-67 revealed that miR-382-5p downregu-
lation impairs the ability of PMF CD34+ cells to pro-
liferate (Fig. 6B). These results were further confirmed
by immunofluorescence analysis for the detection of
Ki-67 antigen, which shows a reduction in proliferat-
ing Ki-67-positive cells after miR-382-5p inhibition
(Fig. 6C,D). These data suggested that miR-382-5p
inhibition could impair the proliferation capability of
PMF CD34+ cells.
3.6. Transforming Growth Factor-b1 induces ROS
production in CB CD34+ cells through the
modulation of miR-382-5p/SOD2 axis
Transforming growth factor beta 1 is a key mediator
of inflammation and fibrosis, widely described as
involved in PMF pathogenesis (Agarwal et al., 2016)
and able to upregulate miR-382-5p in renal fibrosis
(Kriegel et al., 2010). For this reason, we decided to
study the axis TGF-b1/miR-382-5p/SOD2 in CB
CD34+ cells in order to understand whether it could
be involved in the overproduction of ROS.
To this end, we examined the expression level of
both miR-382-5p and SOD2 at 24 and 48 h after
TGF-b1 treatment. As shown in Fig. 7A, real-time
PCR analysis reveals a strong induction of miR-382-
5p in TGF-b1-treated CD34+ cells compared to
untreated cells. Conversely, we observe a decrease in
SOD2 mRNA at both 24 and 48 h after TGF-b1
treatment (Fig. 7B). The suppression of SOD2 protein
level was further confirmed by western blot analysis
and in situ immunofluorescence (Fig. 7C–E). More-
over, we demonstrated that TGF-b1 treatment induces
a significant reduction in SOD activity and a remark-
able induction of ROS production (Fig. 7F,G).
Overall, these data suggest a direct involvement of
TGF-b1 in ROS accumulation through the modulation
of miR-382-5p/SOD2 axis.
3.7. Galunisertib (LY-2157299) reduces ROS
production in PMF CD34+ cells
Since we have shown the significant role of TGF-b1
in the induction of oxidative stress in normal CD34+
cells, we further tested the potential efficacy of galu-
nisertib, an ALK5 inhibitor in PMF CD34+ cells.
Firstly, we assessed the expression level of miR-382-
5p and SOD2 after treatment with TGF-b1 or galu-
nisertib alone or in combination in PMF CD34+
cells. According to results obtained in normal CD34+
cells, the expression level of miR-382-5p is signifi-
cantly enhanced in TGF-b1-treated cells (Fig. 8A);
conversely, SOD2 mRNA is reduced after TGF-b1
Fig. 6. Effect of miR-382-5p inhibition on PMF CD34+ cell proliferation. (A) Viability measurement was assessed by cell count (cellsmL1)
48 h after the last nucleofection by trypan blue exclusion assay. (B) Percentage of Ki-67-positive cells measured by flow cytometry at 48 h
after the last nucleofection. (C) Representative image of Ki-67 immunofluorescence analysis in PMF CD34+ cells transfected with miR-382-
5p inhibitor or anti-miR-Neg at 48 h after the last nucleofection. Cells were labeled with anti-Ki-67 antibody (red fluorescence), and nuclear
counterstaining was performed with DAPI (blue fluorescence). Scale bar: 20 lm. Original magnification = 40X. To ensure random sampling,
20 images/slide were captured and cells positive for SOD2 were scored. Fluorescence imaging was performed using the Zeiss LSM 510
Meta Confocal Microscope. (D) Quantification of Ki-67 positivity in PMF CD34+ cells transfected with miR-382-5p inhibitor compared to
negative control. At least 200 cells for each experiment were scored. The results are representative of three independent experiments and
are expressed as the mean  SEM. Two-tailed Student’s t-test: *P < .05 versus anti-miR-Neg.
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treatment (Fig. 8B). Galunisertib treatment seems to
restore the expression of both miR-382-5p and SOD2
in TGF-b1-treated cells. In particular, in the presence
of galunisertib alone, miR-382-5p expression is sup-
pressed, whereas SOD2 mRNA is significantly
increased compared to untreated cells (Fig. 8A,B).
Western blot analysis and immunofluorescence further
confirmed these results (Fig. 8C–E). Interestingly,
SOD activity is restored in PMF CD34+ cells stimu-
lated by TGF-b1 upon treatment with galunisertib.
Moreover, we observed that galunisertib alone is able
to restore the basal SOD activity in PMF CD34+
cells (Fig. 8F).
According to our previous results, flow cytometric
analysis of ROS content shows an increase in ROS accu-
mulation upon TGF-b1 treatment, while we observe a
reduction in ROS level in TGF-b1 stimulated cells in the
presence of galunisertib. Remarkably, the effect is also
evident when PMF CD34+ cells are treated with galu-
nisertib alone (Fig. 8G).
Interestingly, in normal CD34+ cells we observed
that the treatment with galunisertib alone did affect
neither miR-382-5p/SOD2 expression (Fig. S3A,B) nor
ROS production (Fig. S3C). However, galunisertib
was able to revert the effects on miR-382-5p/SOD2
expression levels and ROS production in TGF-b1-sti-
mulated CB CD34+ cells (Fig. S3).
Altogether, these results demonstrate that galunis-
ertib is able to abrogate the TGF-b1-driven induction
of oxidative stress in PMF CD34+ cells, pointing out
the importance of the axis TGF-b1/miR-382-5p/SOD2
in PMF pathogenesis.
4. Discussion
In the last decades, growing evidence has highlighted
the role of deregulated miRNA expression in MPN
pathogenesis. In order to identify a series of miRNAs
and coding genes potentially involved in PMF patho-
genesis, we recently obtained gene and miRNA
expression profiles of CD34+ HSPCs from PMF
patients. Integrative analysis of gene and miRNA
expression profiles highlighted miR-382-5p among
miRNAs significantly upregulated in PMF CD34+
cells (Norfo et al., 2014). Of note, miR-382-5p deregu-
lated expression has been previously reported in other
hematological malignancies, such as acute promyelo-
cytic myeloid leukemia (AML-M3; Jongen-Lavrencic
et al., 2008). In addition, we unveiled the key role of
miR-382-5p in HSPC fate decision toward granulocyte
lineage (Zini et al., 2016).
In order to shed light on the role of miR-382-5p in
PMF pathogenesis, we assessed the gene expression
changes induced by miR-382-5p overexpression in nor-
mal CD34+ cells. Among genes downregulated after
miR-382-5p overexpression, we selected SOD2, which
is associated with the most favorable prediction score
according to TargetScanHuman prediction algorithm.
Interestingly, SOD2 expression is decreased in PMF
CD34+ cells compared to healthy subjects (Norfo
et al., 2014).
The SOD antioxidant family is responsible for the
dismutation of the superoxide radical anion in hydro-
gen peroxide and provides an essential defense against
the harmful effect of ROS (Szeto, 2006). High levels of
ROS are known to be involved in the pathogenesis of
several solid cancers and hematological malignancies
(Hurt et al., 2007; Waris and Ahsan, 2006; Zheng
et al., 2013) and to play an important role in the initi-
ation and progression of MPNs (Bjorn and Hassel-
balch, 2015; Vener et al., 2010). Indeed, as previously
reported by Vener et al., MPN patients show signifi-
cantly higher serum ROS level if compared to healthy
donors (Vener et al., 2010). Among SOD family mem-
bers, manganese superoxide dismutase 2 (MnSOD-
SOD2) plays an essential role not only in cancer but
also in a wide range of stress-induced diseases due to
its localization in the mitochondria, where the produc-
tion of ROS is higher compared to the other cellular
compartments (Inoue et al., 2003). In particular,
Fig. 7. Transforming Growth Factor-b1 induces ROS production in CB CD34+ cells through the modulation of miR-382-5p/SOD2 axis. (A,B)
CB CD34+ cells were treated with 5 ngmL1 of TGF-b1 for 48 h. qRT-PCR analysis was performed to evaluate the expression level of miR-
382-5p and SOD2 upon TGF-b1 treatment at different time points: before treatment (T0), 24, and 48 h. U6 snRNA and GAPDH were used
as internal controls, and untreated sample was used as calibrator. (C) SOD2 protein level was evaluated by western Blot analysis in lysates
from TGF-b1-treated and untreated cells 24 and 48 h after treatment. b-Actin protein level is reported as loading control. (D)
Immunofluorescence analysis of SOD2 (green fluorescence) in TGF-b1-treated and untreated cells at 24 h after treatment. Nuclear
counterstaining was performed with DAPI (blue fluorescence). Scale bar, 20 lm. Original magnification = 40X. To ensure random sampling,
20 images/slide were captured and cells positive for SOD2 were scored. Fluorescence imaging was performed using the Zeiss LSM 510
Meta Confocal Microscope. (E) Quantification of SOD2 positivity in CD34+ treated with TGF-b1 compared to untreated cells. At least 200
cells for each experiment were scored. (F) TGF-b1 effect on SOD activity (UmL1) at 24 h after treatment. (G) ROS level measured by DCF
staining 24 and 48 h after TGF-b1 treatment. The results are representative of three independent experiments and are expressed as the
mean  SEM. Two-tailed Student’s t-test: **P < .01 versus untreated cells; *P < .05 versus untreated cells.
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SOD2 has been described as a tumor suppressor gene
(Van Remmen et al., 2003) and its decreased expres-
sion level has been reported in a wide variety of dis-
eases (Wang et al., 2016) (Hitchler et al., 2008),
including hematological malignancies (Hurt et al.,
2007).
For this reason, we decided to investigate the poten-
tial involvement of the axis miR-382-5p/SOD2 in the
induction of oxidative stress in normal and PMF
CD34+ cells. Firstly, we demonstrated that SOD2 is a
real target of miR-382-5p by means of luciferase repor-
ter assay. According to these data, we observed a sig-
nificant downregulation of SOD2 at both mRNA and
protein level upon miR-382-5p overexpression in
CD34+ cells. Furthermore, we showed that enforced
miR-382-5p expression leads to a reduction in SOD
activity, which in turn determines a significant ROS
accumulation and the consequent increase in DNA
oxidation.
Moreover, we demonstrated that miR-382-5p over-
expression stimulates CD34+ cell proliferation. Since
elevated ROS level has been reported to promote
mitosis in CD34+ cells (Hole et al., 2010), and
enhanced SOD2 activity has been associated with pro-
liferation inhibition in several cell lines (Oberley,
2005), we hypothesized that miR-382-5p could act on
cell proliferation through the modulation of SOD2
expression and ROS overproduction.
As previously reported by Norfo et al., while miR-
382-5p expression is increased, SOD2 mRNA is
decreased in PMF CD34+ cells (Norfo et al., 2014).
Therefore, in order to confirm that miR-382-5p is a
Fig. 8. Galunisertib (LY-2157299) restores SOD2 activity and reduces ROS accumulation in PMF CD34+ cells. PMF CD34+ cells were
treated with TGF-b1 or galunisertib (Inh) alone or TGF-b1 and galunisertib (TGF-b1+Inh) in combination. Untreated cells were used to
normalize the data. (A,B) qRT-PCR analysis was performed to evaluate the expression level of miR-382-5p and SOD2 at 24 h after
treatments. U6 snRNA and GAPDH were used as internal controls. (C) Western blot analysis was performed after 24 h of treatment on the
whole-cell lysate from TGF-b1/TGF-b1+Inh/Inh-treated and untreated cells. b-actin protein level is reported as loading control. (D)
Immunofluorescence analysis of SOD2 (green fluorescence) in TGF-b1/TGF-b1+Inh/Inh-treated and untreated cells at 24 h after treatments.
Nuclear counterstaining was performed with DAPI (blue fluorescence). Scale bar, 20 lm. Original magnification = 40X. To ensure random
sampling, 20 images/slide were captured and cells positive for SOD2 were scored. Fluorescence imaging was performed using the Zeiss
LSM 510 Meta Confocal Microscope. (E) Quantification of SOD2 positivity. At least 200 cells for each experiment were scored. (F) SOD
activity (UmL1) has been determined after 24 h of TGF-b1/TGF-b1+Inh/Inh treatments and compared to untreated cells. (G) Level of ROS
production measured by DCF staining 24 h after TGF-b1/TGF-b1+Inh/Inh treatment. The results are representative of three independent
experiments and are expressed as the mean  SEM. Two-tailed Student’s t-test: **P < .01 versus untreated cells; *P < .05 versus
untreated cells. #P < 0.05 versus TGF-b1-treated cells. Inh, inhibitor (galunisertib).
Fig. 9. The axis TGF-b1/miR-382-5p/
SOD2. The axis TGF-b1/miR-382-5p/SOD2
as mechanism underlying the
overproduction of ROS in CD34+ PMF
cells. ROS level could increase as a
consequence of: (a) the release of pro-
inflammatory cytokines from granulocytes
induced by miR-382-5p overexpression;
(b) the enhanced expression of miR-382-
5p, which reduces the expression of its
target SOD2; (c) the upregulation of miR-
382-5p by TGF-b1. The TGF-b-receptor I
kinase inhibitor galunisertib could inhibit
the production of ROS by reducing the
expression level of miR-382-5p and
restoring SOD2 activity.
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key player in PMF pathogenesis, we performed silenc-
ing experiments in PMF CD34+ cells. Our results
show that miR-382-5p downregulation restores SOD2
expression and activity, reducing DNA damage and
ROS production. Furthermore, we demonstrated that
miR-382-5p inhibition impairs the proliferation of
PMF CD34+ cells.
As a whole, miR-382-5p overexpression, leading to
SOD2 downregulation in HSPCs, could explain the
overproduction of ROS and therefore the accumula-
tion of oxidative DNA damage observed in PMF
patients. As a consequence, DNA damage generates
genomic instability that leads to the acquisition of new
mutations allowing the clonal evolution and the dis-
ease progression (Marty et al., 2013).
One of the main features underlying PMF pathogen-
esis is the deregulation of the serum levels of pro-
inflammatory cytokines (Tefferi et al., 2011), which
contribute to a state of chronic inflammation (Barosi,
2014; Skov et al., 2013). In particular, several findings
have highlighted the key role of TGF-b signaling in
inflammation through the modulation of cytokine pro-
duction, tumor migration, and angiogenesis (Pickup
et al., 2013; Siegel and Massague, 2003). Moreover,
TGF-b1 has been reported to be a strong inducer of
BM fibrosis (Agarwal et al., 2016), which is another
important feature of PMF. Since it has been demon-
strated that TGF-b1 stimulates miR-382-5p expression
during renal fibrosis (Kriegel et al., 2010), we investi-
gated whether it could be able to regulate the miR-
382-5p expression in normal CD34+ cells. Here we
demonstrated that TGF-b1 treatment enhances miR-
382-5p expression and in turn suppresses SOD2 activ-
ity in normal CD34+ cells. According to our previous
results, we highlighted an increase in ROS production
after TGF-b1 treatment, probably due to a reduction
in SOD2 activity.
Finally, in order to further confirm the involvement
of the axis TGF-b1/miR-382-5p/SOD2 in PMF
pathogenesis, we inhibited TGF-b1 pathway in PMF
CD34+ cells using the TGF-b-receptor I kinase inhibi-
tor galunisertib. Among the TGF-b inhibitors, galu-
nisertib preclinical efficacy has been already tested in
different mouse models (Yue et al., 2017), demon-
strating a strong effect in reversing or reducing BM
fibrosis. Moreover, it has been demonstrated that
galunisertib is a strong inhibitor of TGF-b signaling
in hematopoietic cells (Zhou et al., 2011). Here we
showed that galunisertib is able to revert the effects
induced by TGF-b1 in both normal and PMF CD34+
cells. However, galunisertib alone reduces miR-382-5p
expression and increases SOD2 activity only in PMF
samples. Interestingly, galunisertib is also able to
reduce ROS accumulation in PMF CD34+ cells.
These results are in line with the evidence that TGF-
b1 signaling is a hyperactivated pathway in MPNs
(Kota et al., 2008).
Our data support the idea that the chronic state of
inflammation can itself promote ROS accumulation,
which in turn generates more inflammation. Moreover,
since we have already demonstrated that miR-382-5p
stimulates the granulocyte lineage (Zini et al., 2016),
we hypothesized that the increased release of pro-
inflammatory cytokines (i.e., TGF-b1) from granulo-
cytes themselves could activate the miR-382-5p/SOD2
axis in PMF CD34+ cells sustaining the high oxidative
stress state (Fig. 9).
In summary, we propose a new role for TGF-b1 as
a key mediator in ROS overproduction and we bring
further evidence of its contribution in establishing a
state of chronic inflammation. Strikingly, we identified
a negative correlation between the expression level of
SOD2 and the grade of BM fibrosis in PMF, suggest-
ing that ROS accumulation caused by SOD2 reduction
could favor the TGF-b1-driven progression of fibrosis
(Fig. S4).
Moreover, the reduction in ROS content induced by
galunisertib in PMF CD34+ cells indicates that it
should be an effective therapy to decrease the oxida-
tive stress produced and sustained by the increased
level of TGF-b1 in PMF patients.
As a whole, our data suggest that the combination
therapy of galunisertib with JAK2 inhibitors, which is
currently the gold standard for PMF therapy, should
represent a novel therapeutic option.
5. Conclusions
Here we describe a new role of TGF-b1 as ROS indu-
cer. Alongside its well-known function in PMF fibrotic
process, we demonstrated that TGF-b1 increases the
production of ROS through the modulation of the axis
miR-382-5p/SOD2. Moreover, we shed light on the
novel therapeutic potential of galunisertib, a TGF-b1
inhibitor, in reducing ROS accumulation and oxidative
stress in PMF CD34+ cells.
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